Literature DB >> 30429592

Durability and Decay of Treatment Benefit of Cognitive Behavioral Therapy for Irritable Bowel Syndrome: 12-Month Follow-Up.

Jeffrey M Lackner1, James Jaccard2, Christopher D Radziwon1, Rebecca S Firth1, Gregory D Gudleski1, Frank Hamilton3, Leonard A Katz1, Laurie Keefer4, Susan S Krasner1,5, Chang-Xing Ma6, Michael D Sitrin1, Darren M Brenner7.   

Abstract

BACKGROUND: There is a need for safe and effective IBS treatments that provide immediate and sustained improvement of IBS symptoms, particularly among more severe patients. The aim was to assess long-term clinical response of cognitive behavioral therapy (CBT) with reference to IBS education.
METHODS: A total of 436 Rome III-diagnosed IBS patients (80% F, M age = 41 years) were randomized to: 4 session home-based CBT (minimal contact (MC-CBT)), 10 session clinic-based CBT (standard (S-CBT)), or 4 session IBS education (EDU). Follow-up occurred at 2 weeks and 3, 6, 9, and 12 months following treatment completion. Treatment response was based a priori on the Clinical Global Improvement Scale (global IBS symptom improvement) and IBS Symptom Severity Scale (IBS-SSS).
RESULTS: Post-treatment CGI gains were generally maintained by MC-CBT patients at quarterly intervals through 12-month follow-up with negligible decay. For MC-CBT and S-CBT, 39 and 33% of respondents maintained treatment response at every follow-up assessment. The corresponding percent for EDU was 19%, which was significantly lower (p < 0.05) than for the CBT groups. On the IBS-SSS, therapeutic gains also showed a pattern of maintenance with trends towards increased efficacy over time in all conditions, with the mean unit reductions between baseline and follows-up being approximately -76 at immediate and approximately -94 at 12 months (-50 = clinically significant).
CONCLUSIONS: For treatment-refractory IBS patients, home- and clinic-based CBT resulted in substantial and enduring relief of multiple IBS symptoms that generally extended to 12-month post treatment.

Entities:  

Mesh:

Year:  2019        PMID: 30429592      PMCID: PMC6737527          DOI: 10.1038/s41395-018-0396-x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  21 in total

1.  Multiple imputation of discrete and continuous data by fully conditional specification.

Authors:  Stef van Buuren
Journal:  Stat Methods Med Res       Date:  2007-06       Impact factor: 3.021

Review 2.  Irritable Bowel Syndrome.

Authors:  Alexander C Ford; Brian E Lacy; Nicholas J Talley
Journal:  N Engl J Med       Date:  2017-06-29       Impact factor: 91.245

Review 3.  American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation.

Authors:  Alexander C Ford; Paul Moayyedi; Brian E Lacy; Anthony J Lembo; Yuri A Saito; Lawrence R Schiller; Edy E Soffer; Brennan M R Spiegel; Eamonn M M Quigley
Journal:  Am J Gastroenterol       Date:  2014-08       Impact factor: 10.864

4.  The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress.

Authors:  C Y Francis; J Morris; P J Whorwell
Journal:  Aliment Pharmacol Ther       Date:  1997-04       Impact factor: 8.171

Review 5.  Irritable bowel syndrome.

Authors:  Paul Enck; Qasim Aziz; Giovanni Barbara; Adam D Farmer; Shin Fukudo; Emeran A Mayer; Beate Niesler; Eamonn M M Quigley; Mirjana Rajilić-Stojanović; Michael Schemann; Juliane Schwille-Kiuntke; Magnus Simren; Stephan Zipfel; Robin C Spiller
Journal:  Nat Rev Dis Primers       Date:  2016-03-24       Impact factor: 52.329

6.  Rapid response to cognitive behavior therapy predicts treatment outcome in patients with irritable bowel syndrome.

Authors:  Jeffrey M Lackner; Gregory D Gudleski; Laurie Keefer; Susan S Krasner; Cathrine Powell; Leonard A Katz
Journal:  Clin Gastroenterol Hepatol       Date:  2010-02-17       Impact factor: 11.382

7.  Internet-delivered exposure-based treatment vs. stress management for irritable bowel syndrome: a randomized trial.

Authors:  Brjánn Ljótsson; Erik Hedman; Erik Andersson; Hugo Hesser; Perjohan Lindfors; Timo Hursti; Sara Rydh; Christian Rück; Nils Lindefors; Gerhard Andersson
Journal:  Am J Gastroenterol       Date:  2011-05-03       Impact factor: 10.864

Review 8.  Design of treatment trials for functional gastrointestinal disorders.

Authors:  E Jan Irvine; William E Whitehead; William D Chey; Kei Matsueda; Michael Shaw; Nicholas J Talley; Sander J O Veldhuyzen van Zanten
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

Review 9.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

Authors:  D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

10.  Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility.

Authors:  Jeffrey M Lackner; James Jaccard; Susan S Krasner; Leonard A Katz; Gregory D Gudleski; Kenneth Holroyd
Journal:  Clin Gastroenterol Hepatol       Date:  2008-06-04       Impact factor: 11.382

View more
  9 in total

Review 1.  Brain-Gut Therapies for Pediatric Functional Gastrointestinal Disorders and Inflammatory Bowel Disease.

Authors:  Hannibal Person; Laurie Keefer
Journal:  Curr Gastroenterol Rep       Date:  2019-03-12

2.  Minimal-Contact Versus Standard Cognitive Behavioral Therapy for Irritable Bowel Syndrome: Cost-Effectiveness Results of a Multisite Trial.

Authors:  Laura J Dunlap; James Jaccard; Jeffrey M Lackner
Journal:  Ann Behav Med       Date:  2021-10-04

Review 3.  Psychological comorbidity in gastrointestinal diseases: Update on the brain-gut-microbiome axis.

Authors:  Hannibal Person; Laurie Keefer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-12-14       Impact factor: 5.067

Review 4.  Irritable bowel syndrome in midlife women: a narrative review.

Authors:  Pei-Lin Yang; Margaret M Heitkemper; Kendra J Kamp
Journal:  Womens Midlife Health       Date:  2021-05-31

5.  Presentation and Characteristics of Abdominal Pain Vary by Irritable Bowel Syndrome Subtype: Results of a Nationwide Population-Based Study.

Authors:  Eric D Shah; Christopher V Almario; Brennan M Spiegel; William D Chey
Journal:  Am J Gastroenterol       Date:  2020-02       Impact factor: 12.045

6.  Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement.

Authors:  Jonathan P Jacobs; Arpana Gupta; Jeffrey M Lackner; Ravi R Bhatt; Jacob Brawer; Kan Gao; Kirsten Tillisch; Venu Lagishetty; Rebecca Firth; Gregory D Gudleski; Benjamin M Ellingson; Jennifer S Labus; Bruce D Naliboff; Emeran A Mayer
Journal:  Microbiome       Date:  2021-11-30       Impact factor: 14.650

7.  Studies on irritable bowel syndrome associated with anxiety or depression in the last 20 years: A bibliometric analysis.

Authors:  Yuanfang Chen; Baotao Lian; Peize Li; Simeng Yao; Zhengkun Hou
Journal:  Front Public Health       Date:  2022-08-15

8.  Specific and common mediators of gastrointestinal symptom improvement in patients undergoing education/support vs. cognitive behavioral therapy for irritable bowel syndrome.

Authors:  Jeffrey M Lackner; James Jaccard
Journal:  J Consult Clin Psychol       Date:  2021-05

9.  Epidemiologic Burden and Treatment of Chronic Symptomatic Functional Bowel Disorders in the United States: A Nationwide Analysis.

Authors:  Christopher Ma; Stephen E Congly; Kerri L Novak; Paul J Belletrutti; Maitreyi Raman; Matthew Woo; Christopher N Andrews; Yasmin Nasser
Journal:  Gastroenterology       Date:  2020-10-01       Impact factor: 22.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.